Considering that patients with high expression of CTLA-4 was more likely to benefit from immunotherapy of anti-CTLA-4, and that anti-TIM-3 or anti-CTLA-4 could enhance tumor immunity, we speculated that patients in the low-risk group may be more sensitive to CTLA-4 and TIM-3 inhibitors. The gene discussed is CTLA4; the disease is neoplasm.